CG
AKBA icon

Cutler Group’s Akebia Therapeutics AKBA Stock Holding History

Cutler Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,200
Closed -$1K – 4353
2017
Q4 		$1K Sell
5,200
-3,200
-38% -$53.1K ﹤0.01% 4339
2017
Q3 		$26K Buy
8,400
+4,700
+127% +$72.3K ﹤0.01% 2862
2017
Q2 		$6K Sell
3,700
-6,500
-64% -$82.4K ﹤0.01% 4625
2017
Q1 		$4K Sell
10,200
-57,800
-85% -$564K ﹤0.01% 4845
2016
Q4 		$35K Buy
68,000
+9,700
+17% +$83.5K ﹤0.01% 2886
2016
Q3 		$49K Buy
58,300
+9,800
+20% +$83.3K ﹤0.01% 2482
2016
Q2 		$41K Buy
+48,500
New +$423K ﹤0.01% 2554
2016
Q1 		– Sell
-2,100
Closed -$2K – 6403
2015
Q4 		$2K Buy
+2,100
New +$21.4K ﹤0.01% 5492

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $715M AUM 19.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cutler Group's AKBA Position: Q4 2022 in Review

Cutler Group sold out of Akebia Therapeutics (AKBA) in Q4 2022, closing a stake of 3,400 shares — an estimated $1K sold.

Cutler Group first reported a position in AKBA in Q4 2015 and held it in 15 quarters. The position peaked at $367K in Q3 2017. 75 funds tracked by Wall St. Rank hold AKBA as of Q4 2022.

  • Cutler Group reported no remaining Akebia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 3,400 Akebia Therapeutics shares in Q4 2022, an estimated $1K.
  • Cutler Group first reported a position in Akebia Therapeutics in Q4 2015 and held it in 15 quarters.
  • Cutler Group's Akebia Therapeutics position peaked at $367K in Q3 2017.
  • 75 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.